
12/30/2024
Johnson & Johnson has taken a groundbreaking step by seeking FDA approval for SPRAVATO® (esketamine) as the first-ever monotherapy for adults battling treatment-resistant depression (TRD). This innovative nasal spray has already made waves in combination treatments, and its new application as a standalone option brings hope to millions.
Key Highlights Include:
🌟 Rapid Relief: Phase 4 clinical trials show significant improvement in symptoms within just 24 hours of the first dose, with effects lasting at least 4 weeks.
🌟 Extensive Research: Backed by over a decade of studies, including 31 clinical trials and real-world data from more than 100,000 patients worldwide.
🌟 Global Reach: Already approved in 77 countries for TRD and major depressive disorder (MDD) with acute suicidal ideation or behavior.
SPRAVATO® could revolutionize how we treat depression by offering swift symptom relief and a new sense of hope for patients and their loved ones. If you or someone you know struggles with TRD, contact us today to learn more about available options. 💙
📞 888.412.4546
✉️ carefirstmedicalgroup@gmail.com